Prospectus Supplement, Dated September 23, 2008
|
Filed Pursuant to Rule 424(b)(7) | |
(To Prospectus dated July 30, 2007)
|
File No. 333-144953 |
S-1
Maximum | ||||||||||||||||||||
Number of | ||||||||||||||||||||
Shares of | ||||||||||||||||||||
Number of Shares of Common | Common | Number of Shares of Common | ||||||||||||||||||
Stock Beneficially Owned | Stock Being | Stock Beneficially Owned After | ||||||||||||||||||
Before this Offering | Sold in this | this Offering | ||||||||||||||||||
Selling Stockholder | Number | Percent | Offering | Number | Percent | |||||||||||||||
Abingworth Bioventures II A LP |
270,356 | * | 86,000 | 184,356 | * | |||||||||||||||
Abingworth Bioventures III A LP |
468,008 | * | 100,096 | 367,912 | * | |||||||||||||||
Abingworth Bioventures III B LP |
285,692 | * | 61,102 | 224,590 | * | |||||||||||||||
Abingworth Bioventures III C LP |
171,124 | * | 36,602 | 134,522 | * | |||||||||||||||
Abingworth Bioventures III Executives LP |
7,452 | * | 1,594 | 5,858 | * | |||||||||||||||
Abingworth Bioequities Master Fund Ltd. |
285,790 | * | 74,094 | 211,696 | * | |||||||||||||||
Amadeus II Affiliates Fund LP |
82,568 | * | 10,716 | 71,852 | * | |||||||||||||||
Amadeus II A LP |
1,238,570 | 1.00% | 160,754 | 1,077,816 | * | |||||||||||||||
Amadeus II B LP |
825,714 | * | 107,170 | 718,544 | * | |||||||||||||||
Amadeus II C LP |
577,998 | * | 75,018 | 502,980 | * | |||||||||||||||
Amadeus II D GMBH & Co KG |
27,524 | * | 3,572 | 23,952 | * | |||||||||||||||
Andrew C Rockefeller |
70,740 | * | 23,580 | 47,160 | * | |||||||||||||||
Bristol Investment Fund, Ltd. |
18,522 | * | 18,522 | | * | |||||||||||||||
Caduceus Capital II, LP |
39,558 | * | 39,558 | | * | |||||||||||||||
Caduceus Capital Master Fund Ltd. |
83,126 | * | 83,126 | | * | |||||||||||||||
Capital Ventures International |
83,352 | * | 83,352 | | * | |||||||||||||||
Clarion Capital Corporation |
64,564 | * | 18,522 | 46,042 | * | |||||||||||||||
Cranshire Capital, LP |
17,200 | * | 17,200 | | * | |||||||||||||||
DAFNA LifeScience Ltd. |
9,260 | * | 9,260 | | * | |||||||||||||||
DAFNA LifeScience Select Ltd. |
9,260 | * | 9,260 | | * | |||||||||||||||
HHMI Investments, LP |
9,334 | * | 9,334 | | * | |||||||||||||||
HFR SHC Aggressive Master Trust |
12,518 | * | 12,518 | | * | |||||||||||||||
Hudson Bay Fund LP1 |
94,180 | * | 94,180 | | * | |||||||||||||||
Hudson Bay Overseas Fund Ltd1 |
191,212 | * | 191,212 | | * | |||||||||||||||
Enable Growth Partners, LP |
85,566 | * | 85,566 | | * | |||||||||||||||
Enable Opportunity Partners |
14,484 | * | 14,484 | | * | |||||||||||||||
Estate of Charles E. Murphy, Jr. |
25,798 | * | 25,798 | | * | |||||||||||||||
Leerink Swann LLC 2,3,4 |
263,290 | * | 263,290 | | * | |||||||||||||||
OTA LLC 3,4 |
1,310,526 | 1.06% | 1,310,526 | | * | |||||||||||||||
Paul M. W. Bruckman |
58,478 | * | 17,198 | 41,280 | * | |||||||||||||||
Portside Growth and Opportunity Fund |
56,156 | * | 56,156 | | * | |||||||||||||||
PW Eucalyptus Fund Ltd. |
7,000 | * | 7,000 | | * | |||||||||||||||
Rockmore Investment Master Fund Ltd. |
29,974 | * | 26,034 | 3,940 | * | |||||||||||||||
SF Capital Partners Ltd. |
541,806 | * | 478,154 | 63,652 | * | |||||||||||||||
Shea Venture, LLC |
83,420 | * | 29,652 | 53,768 | * | |||||||||||||||
SRB Greenway Capital, LP |
6,776 | * | 6,776 | | * | |||||||||||||||
SRB Greenway Capital (QP), LP |
45,172 | * | 45,172 | | * | |||||||||||||||
SRB Greenway Offshore Operating Fund, LP |
3,612 | * | 3,612 | | * | |||||||||||||||
Steeple Capital Fund I LP |
1,780 | * | 1,780 | | * | |||||||||||||||
Steeple Capital Fund II LP |
17,032 | * | 17,032 | | * | |||||||||||||||
Steeple Capital Offshore Fund Ltd. |
28,774 | * | 28,774 | | * | |||||||||||||||
Tang Capital Partners, LP |
94,466 | * | 94,466 | | * | |||||||||||||||
UBS Eucalyptus Fund LLC |
62,624 | * | 62,624 | | * | |||||||||||||||
UBS OConnor LLC F/B/O: OConnor PIPES
Corporate Strategies Master Ltd. |
71,806 | * | 71,806 | | * | |||||||||||||||
ValueAct Capital Master Fund |
702,454 | * | 700,566 | 1,888 | * | |||||||||||||||
Walker Smith Capital, LP |
2,928 | * | 2,928 | | * | |||||||||||||||
Walker Smith Capital (QP), LP |
17,850 | * | 17,850 | | * | |||||||||||||||
Walker Smith International Fund, Ltd. |
25,448 | * | 25,448 | | * |
* | Less than 1%. | |
(1) | Sander Gerber, Yoav Roth and Charles Winkler share voting and investment power over these securities. Each of Sander Gerber, Yoav Roth and Charles Winkler disclaims beneficial ownership over the securities held by Hudson Bay Overseas Fund Ltd and Hudson Bay Fund LP. This selling stockholder has represented to us that it acquired the securities offered for its own account in the ordinary course of business and that at the time it acquired the securities, it had no agreements, plans or understandings, directly or indirectly, to distribute the securities. | |
(2) | Jonathan Fleming is a director of Leerink Swann Holdings, LLC, which owns all of the member interests of Leerink Swann LLC. He is also the general partner of OBP Management IV L.P., the general partner of Oxford Bioscience Partners IV L.P. and mRNA Fund II L.P. Oxford Bioscience Partners IV L.P. and mRNA Fund II L.P. were stockholders of Solexa, Inc. until Solexa, Inc. was acquired by Illumina, Inc. in January 2007. | |
(3) | The selling stockholder has identified itself as a broker-dealer that is registered under the Securities Exchange Act of 1934, as amended. | |
(4) | The selling stockholder has represented to us that, at the time it acquired the relevant securities, it did not have any agreements or understandings, directly or indirectly, with any person to distribute the securities. |
S-2